Posted by Michael Wonder on 04 Nov 2021
Epizyme receives fast track designation from U.S. FDA and announces initiation of Phase 1/1b study of its novel SETD2 inhibitor, EZM0414
4 November 2021 - Epizyme today announced that the U.S. FDA has granted fast track designation to EZM0414, the Company’s novel, first in class, oral SETD2 inhibitor, as an investigational agent for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma .
In addition, the Company has initiated a Phase 1/1b study to evaluate safety and determine the optimal dose of EZM0414.
